Maria E. Cabanillas MD FACE

Thyroid

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Cabanillas is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cabanillas' full profile Already have an account?

Education & Training

Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2009
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1998 - 2001
University of Puerto Rico School of MedicineClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2028
TN State Medical License 2022 - 2028
LA State Medical License 2022 - 2027
MS State Medical License 2022 - 2027
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TX State Medical License 2001 - 2026
WA State Medical License 2022 - 2026
AL State Medical License 2023 - 2025
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

A Study of Actonel for the Prevention of Bone Loss
COMPLETED
PHASE3
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
UNKNOWN
PHASE1, PHASE2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
COMPLETED
PHASE2

Publications & Presentations

PubMed

TERT Promoter Variants, Older Age, and Prognosis in Papillary Thyroid Carcinoma.
Vicente R Marczyk, Sophie Li, Chia Chin Wu, Matthew A Loberg, Ying Henderson
JAMA Otolaryngology-- Head & Neck Surgery. 2026-08-20
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.
Steven G Waguespack, Marcia S Brose, Jessica J Lin, Ray McDermott, Mohammed Almubarak
Endocrine-Related Cancer. 2026-08-01
Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications.
David Z Allen, S Mohsen Hosseini, Mark Zafereo, Miriam Lango, Elizabeth Gardner Grubbs
Head & Neck. 2026-08-01

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah,..., The New England Journal of Medicine
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
Thinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
Selective RET Kinase Inhibition for Patients with RET-Altered Cancers
L J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology

Lectures

New Medical Options for the Treatment of Advanced Thyroid Cancer
ENDO 2019 - New Orleans, LA - 3/24/2019
Advanced Thyroid Cancers: New Insights and Treatments
ENDO 2019 - New Orleans, LA - 3/25/2019
From Thyroid Nodules to Thyroid Cancer: Diagnosis and Treatment
ENDO 2019 - New Orleans, LA - 3/25/2019

Authored Content

Adjuvant Pembrolizumab After Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid CancerJuly 2025
Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a CureMay 2025
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

Pembrolizumab Boosts Survival in Anaplastic Thyroid CancerNovember 5th, 2024
New Hope Against a Rare, Aggressive Form of Thyroid CancerOctober 28th, 2024
Atezolizumab plus Targeted Agents Shows Promise in Anaplastic Thyroid CarcinomaOctober 28th, 2024